Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corporation on November 23, 2015, regarding events occurring on November 13 and November 23, 2015. The Company is a medical device firm focused on the CytoSorb® device.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory event rather than financial performance.
Material Changes
The primary material change is the status of the Company's regulatory application:
- Initial Submission: On November 13, 2015, the Company submitted an Expedited Access Pathway (EAP) application to the FDA for the CytoSorb® device to treat sepsis.
- FDA Response: On November 23, 2015, the FDA notified the Company that additional data are necessary to be eligible for EAP designation status consideration.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company is currently scheduling a teleconference with the FDA to discuss the specific amount and type of data required. Management remains confident that the necessary data are available but acknowledges there can be no assurances that the data will be sufficient to obtain EAP designation at this time.
Contingencies and Risks: If EAP designation is not received, the Company plans to seek FDA feedback on its draft data development plan and clinical trial design. Future steps may include resubmitting an EAP application when appropriate data are available or filing an Investigational Device Exemption (IDE) to conduct a sepsis study in the United States towards a Pre-Market Approval (PMA) pathway.
Investor Verification Checklist
- Verify the specific data requirements communicated by the FDA during the upcoming teleconference.
- Confirm the timeline for resubmitting the EAP application or filing an IDE if the current application is not approved.
- Assess the impact of potential delays in regulatory approval on the Company's cash burn and capital requirements.
- Review the Company's existing data set to determine if it aligns with the FDA's request for additional information.